<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Magrioti, V.</style></author><author><style face="normal" font="default" size="100%">Kokotos, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Synthetic inhibitors of group IVA and group VIA phospholipase A&lt;sub&gt;2&lt;/sub&gt;</style></title><secondary-title><style face="normal" font="default" size="100%">Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">189-203</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;span&gt;PLA&lt;sub&gt;2&lt;/sub&gt; is an important signaling enzyme that generates multiple downstream effectors, such as arachidonic acid and PAF, which are key mediators of inflammation as well as other pathophysiological conditions. Inhibition of PLA&lt;sub&gt;2&lt;/sub&gt; is potentially an effective therapy for several inflammatory diseases. In this review, we discuss the various classes of synthetic inhibitors of Group IVA and Group VIA phospholipase A&lt;sub&gt;2&lt;/sub&gt;.&amp;nbsp;&lt;/span&gt;</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record></records></xml>